Rodríguez-Tomàs Elisabet, Arenas Meritxell, Baiges-Gaya Gerard, Acosta Johana, Araguas Pablo, Malave Bárbara, Castañé Helena, Jiménez-Franco Andrea, Benavides-Villarreal Rocío, Sabater Sebastià, Solà-Alberich Rosa, Camps Jordi, Joven Jorge
Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, 43201 Reus, Spain.
Department of Radiation Oncology, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, 43204 Reus, Spain.
Antioxidants (Basel). 2022 Dec 2;11(12):2394. doi: 10.3390/antiox11122394.
Radiotherapy (RT) is part of the standard treatment of breast cancer (BC) because of its effects on relapse reduction and survival. However, response to treatment is highly variable, and some patients may develop disease progression (DP), a second primary cancer, or may succumb to the disease. Antioxidant systems and inflammatory processes are associated with the onset and development of BC and play a role in resistance to treatment. Here, we report our investigation into the clinical evolution of BC patients, and the impact of RT on the circulating levels of the antioxidant enzyme paraoxonase-1 (PON1), cytokines, and other standard biochemical and hematological variables. Gradient Boosting Machine (GBM) algorithm was used to identify predictive variables. This was a retrospective study in 237 patients with BC. Blood samples were obtained pre- and post-RT, with samples of healthy women used as control subjects. Results showed that 24 patients had DP eight years post-RT, and eight patients developed a second primary tumor. The algorithm identified interleukin-4 and total lymphocyte counts as the most relevant indices discriminating between BC patients and control subjects, while neutrophils, total leukocytes, eosinophils, very low-density lipoprotein cholesterol, and PON1 activity were potential predictors of fatal outcome.
放射疗法(RT)是乳腺癌(BC)标准治疗的一部分,因为它对降低复发率和提高生存率有作用。然而,治疗反应差异很大,一些患者可能会出现疾病进展(DP)、第二种原发性癌症,或者可能死于该疾病。抗氧化系统和炎症过程与BC的发生和发展相关,并在治疗抵抗中起作用。在此,我们报告了对BC患者临床演变以及RT对循环抗氧化酶对氧磷酶-1(PON1)、细胞因子以及其他标准生化和血液学变量水平影响的研究。采用梯度提升机(GBM)算法来识别预测变量。这是一项针对237例BC患者的回顾性研究。在放疗前后采集血样,并以健康女性的血样作为对照。结果显示,放疗后8年有24例患者出现疾病进展,8例患者发生了第二种原发性肿瘤。该算法确定白细胞介素-4和总淋巴细胞计数是区分BC患者和对照的最相关指标,而中性粒细胞、总白细胞、嗜酸性粒细胞、极低密度脂蛋白胆固醇和PON1活性是致命结局的潜在预测指标。